US Drug Recall Register
Class II · Moderate risk Terminated Initiated May 21, 2013 (13 years ago)

Metronidazole Injection USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Specific lot numbers of these products have been identified for potential administration port leakage. The potential for leakage is the result of a manufacturing issue which occurred during the sealing of the closure assembly at the administration port.

What was recalled

Metronidazole Injection USP, RTU, 500 mg/100mL in Viaflex Plus Container, Baxter, Deerfield, IL 60015, NDC 0338-1055-48

Recalling firm
Baxter Healthcare Corp.
NDC code
0338-1055-48
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-629-2013

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Metronidazole recalls

See all
Class II · Moderate risk Terminated

Metronidazole 500mg 100ml

Reason Lack of sterility assurance

Sentara Infusion Services D-0306-2023
Class II · Moderate risk Terminated

Metronidazole tablets

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0904-1453-61 D-1056-2022
Class II · Moderate risk Terminated

Metronidazole Vaginal Gel USP

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0781-7077-87 D-1048-2022
Class II · Moderate risk Terminated

Metronidazole Injection

Reason Lack of Assurance of Sterility: there is potential of a leak from the primary container which may result in a potential breach of sterility and contamination of the product.

Claris Lifesciences Inc NDC 36000-001-24 D-0616-2017
Class II · Moderate risk Terminated

Metronidazole 1% Gel

Reason Lack of Assurance of Sterility: There are also CGMP Deviations.

Synergy Rx D-0595-2017